NCT04049409已完成1 期
A Randomized, Double-blinded, Controlled, Single Dosing Phase I Study to Investigate The Pharmacokinetic, Safety and Immunogenicity Characteristics of CMAB809 and Herceptin in Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Area under the concentration-time curve [AUC]
研究概览
简要总结
This is a randomized, double-blinded, controlled Phase I study of CMAB809 administered by intravenous infusion. This study will characterize the pharmacokinetic, safety and immunogenicity of CMAB809 versus Trastuzumab(Herceptin) in healthy male subjects after a single dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Screening
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male volunteers, age ranged 18 to 45 years (both inclusive)
- •A subject with body weight be equal or greater than 50 kg (inclusive) and body mass index (BMI) between 19 and 26 kg/m2 (both inclusive)
- •Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the laboratory reference ranges for the relevant laboratory tests (unless the investigator considers the deviation to be irrelevant for the purpose of the study)
- •Left ventricular ejection fraction (LVEF) within the normal range by echocardiogram (ECHO) at 2 weeks prior to randomization
- •The subjects have the ability to understand the full characteristics and objectives of the study, including the possible risks and side effects of the study; Moreover, the subjects can communicate well with researchers and complete the research according to the regulations
- •Subjects must voluntarily sign ICF prior to the study
排除标准
- •Any clinical signs and symptoms (including blood pressure, pulse, and electrocardiogram) found during medical examination; And those who underwent surgery within 4 weeks before screening; Or plans to operate during the trial period
- •Diagnosed with any clinical history of serious illness or any other disease or physiological conditions which can interfere with the test results
- •Prescription or over-the-counter drugs with a long half-life (greater than 24h) within 1 month prior to administration. Take any other medication that the investigator considers may affect the subject's enrollment within 2 weeks prior to administration. A subject who has participated in any other clinical trial within 3 months before the study drug administration
- •Have used or are using biological products such as monoclonal antibodies or fusion proteins
- •Patients who have or have had chronic hepatitis b, c, syphilis or HIV infection, or who have tested positive for the above infection were deemed unsuitable to participate in this study
- •Those who had been vaccinated within 30 days prior to screening or who needed to be vaccinated between screening and the end of the trial
- •Drug abusers, or those who used soft drugs (e.g., marijuana) 3 months before screening, or took hard drugs (e.g., cocaine, phenyclohexidine, etc.) 1 year before the test, or drank excessive amounts of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250ml) every day, or those who showed positive urine drug screening
- •Blood donation (containing component blood) or lost more than 400 mL of blood within 3 months before screening, or blood transfusion; Blood donation (containing component blood) or blood loss of more than 200 mL within 1 month before screening
- •Related allergies (including allergy to any mouse\human protein or immunoglobulin products, rubber or latex)
- •Those who smoked more than 10 cigarettes per day within 6 months before screening; And those who could not quit during the study period
- •Alcoholics (who drink more than 14 standard units per week), or who have positive result in breath-test of alcohol
- •Vigorous activity for 72h before drug administration; and cannot be avoided within 7 days after drug administration
- •Unable to accept clinical trial center diet
- •Fertile men who were unwilling to use highly effective contraceptives during the trial and for five months after administration
- •The investigator judges the subject not eligible for the study after reviewing clinical laboratory results or other reasons
研究组 & 干预措施
CMAB809
Experimental
干预措施: CMAB809 (Drug)
Trastuzumab
Active Comparator
干预措施: Trastuzumab (Drug)
结局指标
主要结局
Area under the concentration-time curve [AUC]
时间窗: pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose
Area under the concentration-time curve \[AUC\] from 0 to the last time point selected of CMAB809
次要结局
- Cmax(pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose)
- AUC0-∞(pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose)
- Tmax(pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose)
- CL(pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose)
- Vd(pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose)
- T1/2(pre-dose, hour1.5, hour3, hour8, hour24, hour48, hour96, hour168, hour336, hour504, hour672, hour1008, hour1344, hour1680 post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy VolunteersHealthy VolunteersNCT06361355Taizhou Mabtech Pharmaceutical Co.,Ltd128
撤回
1 期
Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy VolunteersHealthy VolunteersNCT05808673Taizhou Mabtech Pharmaceutical Co.,Ltd
招募中
1 期
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson'sParkinson DiseaseNCT06309147Allyx Therapeutics18
尚未招募
1 期
Safety and Tolerability of a Single Intravenous Infusion of BX-U001 in Refractory Rheumatoid ArthritisRheumatoid ArthritisNCT03828344Baylx Inc.16
已完成
1 期
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis VulgarisPsoriasis VulgarisNCT00277225Bristol-Myers Squibb32